Subtype
Renal Pelvis and Ureter Carcinoma
CI-CAN-00003809Explore in graph →
48 active trials1 evidence items
- NCIt
- C7515
Loading cancer entity…
Subtype
CI-CAN-00003809Explore in graph →
Clinical trials
105 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04628767 | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | recruiting | Phase 2 / Phase 3 | 131 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05987241 | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | recruiting | Phase 2 / Phase 3 | 992 | National Cancer Institute (NCI)NIH |
| 2 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT06948552 | Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA | recruiting | Phase 2 | 10 | Henry Ford Health SystemOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07667335 | Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06124976 | Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma | recruiting | Phase 2 / Phase 3 | 70 | Peter BlackOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05775471 | Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer | recruiting | Phase 2 | 21 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07087860 | Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers(RECIPE-B1) | recruiting | Phase 2 | 70 | Mayo ClinicOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06210490 | A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery | recruiting | Phase 2 | 60 | Peking University First HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05912816 | Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients | recruiting | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07225374 | Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC | recruiting | Phase 2 | 48 | Samsung Medical CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | recruiting | Phase 1 / Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07126119 | Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC | recruiting | Phase 2 | 35 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06983210 | Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma(GRAPE) | recruiting | Phase 2 | 43 | Nagoya UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06823427 | 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 | 60 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05917158 | A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma(1) | recruiting | Phase 2 | 30 | Jinling Hospital, ChinaOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06354231 | DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Apr 11, 2024 | clinicaltrials |
Data updated 18 hours agoSource updated Sep 29, 2026source: clinicaltrials